PGI Drug Discovery LLC (Psychogenics) -The Comp
Post# of 30028
Posted On: 08/15/2014 9:49:58 PM
PGI Drug Discovery LLC (Psychogenics)
-The Company and PGI entered into a services agreement pursuant to which PGI will provide certain services to the Company related to PGI’s proprietary analytical systems (refer to Note INTANGABLE ASSETS). The Company agreed to a payment commitment of $450 at a minimum annual rate of $150, for each of three years. The Services Agreement is for a term of the later of 3 years or the completion of any study plan accepted by the parties under the services agreement.
-On January 10, 2014, the Company entered into a license agreement (“PGI License Agreement”) with PGI Drug Discovery, LLC (“PGI”). Pursuant to the terms of the agreement, the Company agreed to pay PGI up to an aggregate of $4,000 in development milestones through NDA submission. Milestone based payments payable by the Company under the PGI License Agreement are as follows: (i) $1,000 upon successful completion of the first Phase 2b clinical study, and (ii) $3,000 million upon submission of a New Drug Application with the United States Food and Drug Administration or a comparable submission outside of the United States.
PsychoGenics Inc. And Roche (RHHBY) Expand Their Drug Discovery Partnership
4/22/2014
TARRYTOWN, N.Y.--(BUSINESS WIRE)--PGI Drug Discovery LLC (PsychoGenics) announced that it has expanded its CNS drug discovery partnership with Roche and extended the agreement for another five years.
In April 2008, PsychoGenics and Roche entered into a drug discovery and development agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. The teams utilize the phenotypic approach in a high throughput manner with SmartCube® to drive chemistry optimization efforts.
-The Company and PGI entered into a services agreement pursuant to which PGI will provide certain services to the Company related to PGI’s proprietary analytical systems (refer to Note INTANGABLE ASSETS). The Company agreed to a payment commitment of $450 at a minimum annual rate of $150, for each of three years. The Services Agreement is for a term of the later of 3 years or the completion of any study plan accepted by the parties under the services agreement.
-On January 10, 2014, the Company entered into a license agreement (“PGI License Agreement”) with PGI Drug Discovery, LLC (“PGI”). Pursuant to the terms of the agreement, the Company agreed to pay PGI up to an aggregate of $4,000 in development milestones through NDA submission. Milestone based payments payable by the Company under the PGI License Agreement are as follows: (i) $1,000 upon successful completion of the first Phase 2b clinical study, and (ii) $3,000 million upon submission of a New Drug Application with the United States Food and Drug Administration or a comparable submission outside of the United States.
PsychoGenics Inc. And Roche (RHHBY) Expand Their Drug Discovery Partnership
4/22/2014
TARRYTOWN, N.Y.--(BUSINESS WIRE)--PGI Drug Discovery LLC (PsychoGenics) announced that it has expanded its CNS drug discovery partnership with Roche and extended the agreement for another five years.
In April 2008, PsychoGenics and Roche entered into a drug discovery and development agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. The teams utilize the phenotypic approach in a high throughput manner with SmartCube® to drive chemistry optimization efforts.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼